Financials
Financial year 2025
LS Pharma from Gembloux, company number BE0779459534, closed financial year 2025 with a result of € 65,358 after tax. For that financial year LS Pharma recorded a gross margin of € 362,120 and equity of € 555,475. Compared with financial year 2024, the result moved from € 77,249 to € 65,358. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 13, 2026.
€ 555,475
▲ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 65,358
▼ 15% vs 2024
Profit after tax over the fiscal year.
€ 185,051
▲ 30% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 551,945.
People and assets in 2025
2.8
▼ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 243,856
▲ 13% vs 2024
€ 87,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 36,786
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 15,000
▼ 8% vs 2024
Loans from banks and other lenders, long and short.
€ 123,442
▲ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 42,923
▼ 3% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 426,639 | € 326,532 | € 348,477 | € 362,120 | ▲ 4% |
| Profit after taxes | € 147,830 | € 100,754 | € 77,249 | € 65,358 | ▼ 15% |
| Equity | € 342,114 | € 412,868 | € 490,117 | € 555,475 | ▲ 13% |
| Total debts | € 267,570 | € 192,870 | € 161,235 | € 193,843 | ▲ 20% |
| Cash | € 187,956 | € 122,978 | € 142,271 | € 185,051 | ▲ 30% |
| Land & buildings | € 52,535 | € 45,982 | € 40,458 | € 35,134 | ▼ 13% |
| Retained profit | € 338,583 | € 409,338 | € 486,587 | € 551,945 | ▲ 13% |
| Dividend | € 39,464 | € 30,000 | € 0 | € 0 | |
| Bank debt | € 33,056 | € 9,723 | € 16,390 | € 15,000 | ▼ 8% |
| Balance sheet total | € 609,684 | € 605,738 | € 651,352 | € 749,318 | ▲ 15% |
| Employees (FTE) | 2.1 | 1.9 | 3.1 | 2.8 | ▼ 0.3 |
Key figures of LS Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LS Pharma?
What happened at LS Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 65,358 (▼ 15% vs 2024). Source: NBB ↗
- New establishment in Gembloux. KBO
- Start of the company according to the CBE. KBO
In short
From € 147,830 profit in 2022 to € 65,358 profit in 2025.
Paid € 154,358 in corporate taxes since 2022.
Best year ever: 2022, with € 147,830 profit.
On average € 129,300 of value added per employee in 2025.
A new publication or filing at LS Pharma? We notify you, reason included.
Follow LS PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind LS Pharma are Laurent Staumont and Chantal Arnould. The same people are also behind CEGEAM IMMO and PHARMACIE DE LONZEE.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Chaussée de Tirlemont, Sauv. 205
5030 Gembloux
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0779.459.534
- VAT number
- BE 0779.459.534
- Registered office
- Chaussée de Tirlemont, Sauv. 205, 5030 Gembloux
- Names & denominations
- LS Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 2021
- Peppol
- Active · Active since 17 Jul 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels